This episode breaks down the FDA's final rule transitioning the Quality System Regulation (21 CFR Part 820) to the ISO 13485-aligned Quality Management System Regulation (QMSR). We cover the February 2, 2026, compliance deadline, the key differences and retained FDA requirements, and the strategic steps medical device manufacturers must take to harmonize their global quality documentation and ensure a seamless transition.

- What is the FDA's new Quality Management System Regulation (QMSR)?

- When is the mandatory deadline to transition from QSR to QMSR?

- How does the new rule align with the global standard ISO 13485?

- Why is simply having an ISO 13485 certificate not enough for compliance?

- Which specific U.S. requirements are being kept in the new QMSR?

- What are the biggest challenges in harmonizing global quality documents?

- What is the first step your company should take to prepare for the 2026 deadline?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. Navigating the FDA's transition to the QMSR while managing global registrations requires expert strategy. We develop efficient pathways for regulatory approval, using advanced AI to compile and manage technical dossiers that meet both new QMSR and international standards. Our local experts in over 30 markets ensure your quality systems are compliant globally. Let us streamline your transition and accelerate your global market access. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.